In July in the Russian pharmacies and hospitals received the first domestic original drug intended for the therapy of melanoma — PD-1 inhibitor c international nonproprietary name fragolina. The drug company BIOCAD has been approved by the Ministry of health for treatment of one of the most aggressive types of cancer — metastatic or inoperable melanoma in late April of this year.
It is planned that the drug will be available to hospitals from the Federal and regional level, and is also distributed through the pharmacy network. The inclusion of the drug in the essential drugs list is expected in early 2021, which will reduce the burden on the health budget.
Prolegomena is the world’s first PD-1 inhibitor based on monoclonal antibodies IgG1 c additional modifications to its effector properties. In the human body every day are formed by the malignant cells, destroying the immune mechanisms before the tumor will grow enough to become a threat to health. Inhibitors of PD-1 activates T-lymphocytes and allow them to recognize and destroy malignant cells.
Before the advent of the domestic market inhibitor therapy of melanoma in Russia was presented nicolumbo and ambrosianeum. According to the Company Headway in 2019, these American drugs were ranked third and fourth lines of the rating of INN on the volume of purchases.